Gary Ulaner, MD, PhD, FACNM, is the Director of Molecular Imaging and Therapy at Hoag Family Cancer Institute, as well as a Clinical Professor of Radiology and Translational Genomics, Keck School of Medicine, University of Southern California.
Dr. Ulaner sat down with us to highlight the line(s) of therapy in which novel RLT-PSMA agents are being developed.
In what line(s) of therapy are novel RLT-PSMA agents being developed?
Dr. Ulaner: So, Pluvicto is FDA approved late in the course of disease for patients who have progressed on hormonal and prior taxane chemotherapy, as was described in the patient population in the VISION trial. There are multiple clinical trials that are investigating the use of these PSMA targeted agents earlier in the course of disease. Trials that come to mind are the ECLIPSE trial, the SPLASH trial, the ARROW trial, that are utilizing different keys to bind to PSMA that are labeled with Lutetium-177. Or in the case of the ARROW trial, Iodine-131, earlier in the course of disease, in patients that have progressed on hormonal therapies, but have yet to be challenged by chemotherapies.
And certainly, patients are looking to become part of these trials because it gives them the option to use the PSMA targeted therapies instead of using chemotherapies. Which have, in my experience, and the experience of many other people, far greater toxicities than these PSMA targeted radioligand therapies. So the opportunity for patients to use the radioligand therapies earlier than chemotherapy, I think, is a big advance.